PE2038 calls on the Scottish Parliament to urge the Scottish Government to commission suitable NHS services for people with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders and to consult patients on their design and delivery. For consideration of the petition, we have been joined by our MSP colleague Michael Marra, who has taken an interest in the petition. Good morning, Mr Marra.
Official Report · Committee
Continued Petitions
People with Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders (PE2038)
Speakers
Choose an MSP to read only their contributions- Jackson Carlaw Con 4
- Michael Marra Lab 2
- Foysol Choudhury Lab 1
The record
7 contributions
link
Good morning, convener.
We previously considered the petition on 4 October last year, when we agreed to write to the Scottish Government and the national services division. The Scottish Government’s response provides information about its engagement work with individuals living with Ehlers-Danlos syndrome and hypermobility spectrum disorders. The submission highlights the Government’s work on the rare disease action plan and states that officials would be happy to meet the petitioner to discuss that work further.
The national services division’s submission explains that a short-life working group that it facilitated found that
“there was a need for specific specialist expertise in Scotland to improve patient care”
but one of the reasons why that work has not progressed is that the national specialist services committee determined that
“care might be better delivered through the development of a set of clinical guidelines, a patient pathway of care or a networked community of practice.”
The response from the petitioner—Ehlers-Danlos Support UK—states:
“This is exactly what we are trying to achieve”,
but it has been informed by Healthcare Improvement Scotland that there is “not enough evidence” to support the creation of guidelines from the Scottish intercollegiate guidelines network. The petitioner has shared that NHS Wales has now
“committed to co-creating a hypermobility pathway for primary care to help GPs diagnose and manage these conditions.”
The petitioner also outlines statistics to support its view that Ehlers-Danlos syndrome and hypermobility spectrum disorders are not necessarily rare disorders, as they often go undiagnosed.
We have received a written submission from our colleague Emma Roddick, who is unable to attend the meeting. Her submission, which is available on the committee’s website, touches on her experience of living with chronic pain and the value of meeting other people who have similar experiences to her own. She acknowledges that doctors
“cannot be expected to know everything”,
but she believes that there should be
“a nationally agreed standard for pain pathways to ensure that people do not fall through the cracks”.
Before we consider what we might do next, I invite Michael Marra to speak to the committee.
09:45
link
I greatly appreciate being afforded the opportunity to address the committee. This is the first time that I have spoken to the committee about the petition, and I would like to provide an update on some of the developments from my involvement with the petition.
My involvement relates to constituents who are living with such conditions and have faced challenges in accessing treatment and support. That includes some who have waited 20 years for a diagnosis. I have lodged a motion for a members’ business debate on the subject, which has gained cross-party support, for which I am grateful. I look forward to having that debate in the chamber when it is scheduled.
Last month, I was pleased to host a round-table meeting in the Parliament with Ehlers-Danlos Support UK and researchers from the University of Edinburgh, Kathryn Berg and Dervil Dockrell, who shared the findings of their recent research into EDS, which revealed that people are waiting decades for a diagnosis, with a large proportion of those people either leaving Scotland to access healthcare in England or paying for private treatment. That demonstrates that there is a clear gap, as that research testifies, in the services that are available in Scotland for people living with HEDS and HSD. For that reason alone, I urge the committee to keep the petition open for further consideration, and I will come on to suggest some potential actions.
Ehlers-Danlos syndromes are a group of 13 heritable connective tissue disorders that are caused by genetic changes that affect connective tissues. Each type of EDS has its own set of features, but common features of various types of EDS include joint hypermobility, skin hyperextensibility and tissue fragility. That can cause a person’s joints to dislocate and their skin to be stretchy. They bruise easily and their wounds can take a long time to heal.
I have heard powerful testimony from constituents on living with such conditions. They have talked about being in constant pain, living with reduced mobility and having a limited quality of life, as well as the impacts on their mental health.
The most common type of EDS is hypermobile EDS, which accounts for about 90 per cent of the cases that are being considered today. There are various statistics on the prevalence of such conditions. The convener referenced some of them in his opening remarks. As he did and as colleagues from EDS UK have done, I point out that there is a crucial distinction between rare and rarely diagnosed. One study found that one in 500 people had a diagnosis of HEDS and HSD, so the matter certainly requires more investigation.
The Scottish Government’s submission on 12 October 2023 stated that the Government was
“considering what additional stakeholder engagement activities may be required throughout 2024.”
It also talked about
“the Rare Disease Implementation Boards’s intention to hold a number of ‘involvement meetings’ early in 2024”.
However, as it states in its latest submission, EDS UK does not feel that those meetings are an appropriate avenue for developing a specific care pathway for EDS, as they cover a range of rare diseases.
The response from the national services division on 13 October 2023 stated:
“The ongoing diagnostic, treatment, and care needs of hEDS and HSD patients are the responsibility of individual Health Boards”.
However, given the experiences of my constituents that I have highlighted and those that have been highlighted through research and the work of EDS UK, that system is simply not working at the moment.
The petitioner’s most recent submission calls for
“A pathway for NHS diagnosis and care for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders ... NICE/SIGN guidelines for Ehlers-Danlos syndromes and hypermobility spectrum disorders ... A coordinated, multidisciplinary approach to diagnosis and care for people with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders”
and, crucially,
“Support and training for healthcare professionals to deliver this.”
I commend the staff and volunteers at EDS UK for their continued determination on the issue.
I note that progress has been achieved in other United Kingdom nations to date. For example, in May, as the convener said, NHS Wales committed to co-creating a hypermobility pathway for primary care to help GPs to diagnose and manage the conditions. Colleagues at EDS UK have met community health pathway teams in Wales, which has helped to progress work on that pathway. Research and lived experience have shown that GPs are often not aware of such conditions or the potential treatment options that are available. Publishing a pathway would give clearer guidance to GPs and lead to improved patient experiences. At the round-table meeting that was held in the Parliament, there was a clear desire from the general practitioner workforce to have such information available to them.
As far as I am aware, we do not have community health pathways in Scotland, but there is the possibility for some collaborative work across the two nations of Scotland and Wales in that regard. I suggest that the committee might want to contact NHS Wales to find out more detail on the progress of that work to date and how it might be applicable to Scotland.
Thank you very much. There were a couple of good suggestions in there.
We should keep the petition open and, as well as doing what Mr Marra suggested, write to the Scottish Government to ask whether it accepts the petitioner’s view that Ehlers-Danlos syndrome and hypermobility spectrum disorders are not necessarily rare diseases, as they are often undiagnosed. In the light of that, we should ask what action is being taken, beyond the rare disease action plan, to improve diagnostic services. We should also highlight the commitment by NHS Wales to co-produce a hypermobility pathway for primary care and ask whether a similar exercise could be undertaken in Scotland.
I note that, in addition to Mr Marra and Emma Roddick, a number of our colleagues—Bob Doris, Angela Constance, Bill Kidd, Pauline McNeill, Màiri McAllan, Daniel Johnson, Martin Whitfield and Michelle Thomson—have all been engaged on the issue, so it has attracted a considerable amount of attention and concern among parliamentary colleagues.
I am happy to take forward all the suggestions that have been made. We might also want to ask about the view that the current way of moving forward might not be the best model to achieve the end result. It would be useful to put that point to the Scottish Government to see what its reaction is, because that view is obviously very clearly felt.
We will keep the petition open. There are a number of ways in which we can continue to pursue the issue. I thank the petitioner for lodging the petition and Michael Marra for joining us this morning.
In this meeting
Everything on 9 Oct 2024 →- 09:30 Decision on Taking Business in Private Procedure · 1
- 09:30 Continued Petitions Petitions · 4
- 09:30 Continued Petitions Petitions · 4
- 09:30 Continued Petitions Petitions · 4
- 09:30 Continued Petitions Petitions · 4
- 09:30 Continued Petitions Petitions · 7
- 09:45 Continued Petitions Petitions · 6
- 10:00 Continued Petitions Petitions · 11
- 10:00 Continued Petitions Petitions · 4
- 10:00 New Petitions Petitions · 3
- 10:00 New Petitions Petitions · 7
- 10:15 New Petitions Petitions · 3
- 10:15 New Petitions Petitions · 4
The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.